Navigation Links
Personal Genome Diagnostics and MolecularMD Collaborate to Provide Advanced Genomic Testing Services to Cancer Drug Developers
Date:10/25/2013

BALTIMORE, Oct. 25, 2013 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx), today announced that it will collaborate with MolecularMD to market a suite of comprehensive personalized medicine services to oncology researchers and drug developers, adding PGDx's expertise in Next-Generation Sequencing (NGS)-based cancer biomarker discovery to MolecularMD's capabilities in the development, validation and global delivery of cancer companion diagnostics. The collaboration is designed to provide a unique specialized service to the pharmaceutical and biotechnology industry, seamlessly spanning the entire spectrum of genomic and clinical trial services used in new drug R&D and clinical development. Under the terms of the agreement, the two companies will co-market each other's services to their pharmaceutical and biotechnology customers.

PGDx provides advanced genome mapping services and analyses to oncology researchers, clinicians and patients. It employs cancer exome analysis, which enables comprehensive, reliable and unbiased genome-wide identification of cancer-related mutations. The company's proprietary methods for genome sequencing and analysis are complemented by its deep expertise in cancer genomics.

MolecularMD provides molecular diagnostics products and services to pharmaceutical and biotechnology drug developers. Its capabilities range from specialty molecular testing services performed in its CLIA-certified and CAP-accredited laboratory to development of companion diagnostics that support new drug registrations. It also provides NGS services for clinical trials, including standard and custom-designed panels that can profile gene alterations relevant to therapeutic response or resistance.

"PGDx focuses on unbiased NGS-based approaches that are most relevant in the early stages of drug discovery and development, which complements MolecularMD's capabilities in the development of companion diagnos
'/>"/>

SOURCE Personal Genome Diagnostics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cedars-Sinai Medical Center to Use Exosome Diagnostics Exosome RNA Biofluid Kits in Neo-Natal Setting and Cancer for Development of Personalized Medicine Diagnostics
2. 2013 SharpBrains Virtual Summit to Discuss Latest on Digital Brain Health, Brain Fitness, Personal Health
3. Sanguine BioSciences Signs Agreements with More than 200 Partners to Enable Efficient Personalized Medicine Research
4. Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
5. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
6. Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets
7. The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris
8. DuPont Tate & Lyle Bio Products Collaborates with RML Incorporated to Develop Bio-Based Solution for Personal Care Products
9. NYSCF scientists create personalized bone substitutes from skin cells
10. Lucintel’s Analysis of Growth Opportunities in Global Polymer Ingredients Used in Personal Care Industry: Market to Reach $3,495 Million by 2017
11. QVC and Fashion Footwear Association of New York Invest in Personalized Breast Cancer Therapy Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2015)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced its results ... fiscal 2014 year-end financial statements and MD&A have been filed on SEDAR ... , 2014 , 2013 Revenue 3,968 , ... 1,326 , 1,703 , 2,231 , ... 3,377 , 4,562 Ebitda* 92 , 418 ...
(Date:4/29/2015)... EAST RUTHERFORD, N.J. , April 29, 2015 ... 2015 financial results will be released on Friday, May 1, ... The Company will host a conference ... Conference Call When: , Friday, ... Dial-in: , 1-888-468-2440 for U.S.1-719-325-2454 for International ...
(Date:4/29/2015)... 2015 The leading Regenerative Veterinary Medicine ... regenerative stem cell therapy has processed more than 11,000 ... discover a successful treatment for horses with potentially fatal ... signed a worldwide exclusive license for adipose-derived (fat derived) ... horse was treated in January 2004. Shortly after, the ...
(Date:4/29/2015)... - Northern Biologics Inc., a privately held biotechnology company ... strategic collaboration with Celgene Corporation.  As part of ... upfront cash payment. It will use the funds ... will have the right to receive additional future ... Under the agreement, Northern Biologics ...
Breaking Biology Technology:Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2Northern Biologics and Celgene Enter Strategic Collaboration 2
... Robotics today announced,that the European Union (EU) ... results of the SafeChemo Project it sponsored ... objectives were to scientifically and,independently establish if ... system for the safe preparation of hazardous ...
... Jan. 5 Baxter,International Inc. and Halozyme Therapeutics, ... start of a Phase III clinical trial of ... as KIOVIG in the European,Union, with Halozyme,s recombinant ... of primary immunodeficiency (PID).,The purpose of this clinical ...
... BMP Sunstone,Corporation (Nasdaq: BJGP ) ("BMP ... Pharmaceutical Co., Ltd., has been granted high tech,status ... is awarded by the PRC to,recognize companies that ... revenues generated by their own proprietary patented or,innovative ...
Cached Biology Technology:Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project 2Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project 3Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project 4Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 2Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 3Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 4Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 5BMP Sunstone Receives High Tech Status 2BMP Sunstone Receives High Tech Status 3
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report to ... for Iris Biometrics in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Latin America . ...
(Date:3/18/2015)... , March 18, 2015 As mobile ... new revolutionary smart wallets and apps continue to be introduced ... entrenched in the mobile payment industry in focus today are:  ... Ltd. (NYSE: BABA ), Apple Inc. (NASDAQ: ... and Facebook Inc. (NASDAQ: FB ) ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... Park, MD (July 27, 2010) -- Drug delivery inside ... a maze of aqueous solutions, lipid membranes, and barriers ... reported in the American Institute of Physics publication the ... model that accurately predicts the hydration free energy (HFE) ...
... Park, MD (July 27, 2010) -- Fluids experts writing ... is published by the American Institute of Physics, are ... accurately probe the properties of turbulence near walls. High-Reynolds-number ... in aeronautics, naval applications, energy conversion processes, manufacturing, mixing ...
... fish scientist has received the Robert H. Gibbs, Jr. ... knowledge of fish diversity. The honor to Dr. ... the Ichthyology Department, was announced earlier this month in ... Society of Ichthyologists and Herpetologists. The Gibbs award is ...
Cached Biology News:
...
...
... Zero Blunt TOPO PCR Cloning Kit ... for high-efficiency (>=95%) cloning of blunt-end ... polymerases. The kit includes the linearized ... for 5-minute bench-top ligations without ligase ...
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Biology Products: